Diverse combination regimens involving ICIs (PD-1, PD-L1, and CTLA-4 inhibitors) with inhibitors of vascular endothelial growth factor (VEGF) pathway such as anti-VEGF antibody, anti-VEGFR antibody, or VEGFR tyrosine kinase inhibitor (TKI) had shown improved clinical benefit compared to ICIs or antiangiogenic monotherapy, providing a hopeful solution to improve SCLC outcomes (Song et al., 2020; Socinski et al., 2021; Cheng A. et al., 2022). This evidence concerns the gene VEGFA and small cell lung carcinoma.